Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Ticker SymbolDYAI
Company nameDyadic International Inc
IPO dateNov 05, 2004
CEOMr. Mark A. Emalfarb
Number of employees6
Security typeOrdinary Share
Fiscal year-endNov 05
Address1044 North U.S. Highway One
CityJUPITER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33477
Phone15617438333
Websitehttps://dyadic.com/
Ticker SymbolDYAI
IPO dateNov 05, 2004
CEOMr. Mark A. Emalfarb
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data